Resource
Elrexfio® (elranatamab-bcmm) is a B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. In August 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Elrexfio for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have…
Resource
This booklet is designed to help patients with myeloma who already have neuropathy as well as to inform patients who might be able to avoid or to mitigate the development of this problem. We hope that this booklet is also a resource for the patient’s care partners, who can help recognize…
Resource
Velcade® (bortezomib) is a proteasome inhibitor that plays a role throughout the myeloma disease course, from induction therapy for the newly diagnosed, to a possible role as part of conditioning for stem cell transplant, to consolidation/maintenance therapy, to treatment for those whose myeloma…
Resource
Overview
T-cell redirecting therapies (TCRTs), including CAR T-cell therapy and bispecific T-cell engagers (TCEs), are transforming how multiple myeloma (MM) is treated. These innovative therapies target proteins like BCMA and GPRC5D, with several options already approved worldwide and more in…
Resource
The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and refractory myeloma. Sarclisa binds to myeloma cells to kill them directly, and also recruits other immune system cells to kill myeloma cells.
Resource
Patients with myeloma may experience fatigue caused by the disease itself or by treatment for myeloma, as well as by other medical problems or their treatment. This booklet contains a discussion of fatigue management strategies, as well as suggestions for recording and reporting fatigue to your…
Resource
Darzalex® (daratumumab) is the first FDA-approved monoclonal antibody that targets the CD38 protein on the surface of myeloma cells. The original formulation of Darzalex is administered as an intravenous infusion, and the FDA has also approved Darzalex Faspro® (daratumumab +…
Resource
Abecma® (idecabtagene vicleucel, “ide-cel”) is the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food and Drug Administration (FDA) for use in myeloma. Abecma is a personalized immune cell therapy delivered as…
Resource
Pomalyst (pomalidomide) is an immunomodulatory agent, a drug that can modify, enhance, or suppress the functioning of the immune system. Pomalyst was approved by the U.S. Food and Drug Administration (FDA) in 2013 for the treatment of adult patients with relapsed and refractory myeloma. It is used…
Resource
The triplet VRd regimen is approved in the United States and in the European Union for patients with previously untreated myeloma who are ineligible for transplant. The VRd combination is highly effective and well tolerated.
Resource
This tool was developed in collaboration with myeloma patients and caregivers, leaders of myeloma support groups, and the IMF Nurse Leadership Board. Discuss this tool with your treatment team and healthcare providers.
Resource
The following is a summary of the paper:
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group. Dimopoulos, Meletios A et al. The Lancet Oncology, Volume 24, Issue 7, e293 - e311. Visit…
Resource
Alkylators are chemotherapy drugs that interfere with the DNA replication process, causing cell death as a result. Alkylators were the earliest effective drugs used in myeloma. Bendamustine, cyclophosphamide, and melphalan are still used for the treatment of patients with myeloma.
Resource
The summer edition of Myeloma Today includes a report on the 2024 Summit of the IMF’s International Myeloma Working Group (IMWG), which brings together top global experts in myeloma research and clinical care who conduct collaborative basic, clinical, and…
Resource
Kyprolis® (carfilzomib) is a proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2012 for the treatment of relapsed or refractory myeloma. Kyprolis works by blocking the activity of enzyme complexes called proteasomes, which are important for maintaining balance within…
Resource
The management of relapsed or refractory multiple myeloma presents a significant clinical challenge, despite recent advancements in treatment modalities. Novel immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA), have…
Resource
Thalidomide is an oral drug that was first used for the treatment of patients with myeloma in 1997. It was the first immunomodulatory agent approved by the FDA for myeloma. Currently, thalidomide is used infrequently in the U.S., but it is still sometimes used during late-stage disease, in cases of…
Resource
This document discusses the toxicity and management of cytokine release syndrome and neurological complications associated with bispecific antibody therapy. Cytokine release syndrome is a systemic inflammatory reaction caused by T-cell activation, leading to the release of pro-inflammatory…
Resource
The spring edition of Myeloma Today, is filled with promising developments in the field of myeloma. Here are some highlights: Two New FDA Approvals: Abecma® and Carvykti® CAR T-cell therapies have been approved for earlier use in the myeloma journey,…
Resource
This document discusses the disparities faced by African American patients with multiple myeloma in terms of incidence, timely diagnosis, access to treatment, clinical trial participation, and healthcare utilization. The disparities are influenced by both biologic and non-biologic factors. …
Resource
In the Fall 2023 edition, IMF Chief Medical Officer Dr. Joseph Mikhael highlights the approval of two new myeloma drugs. Those drugs, ELREXFIO™ and TALVEY™, are both bispecific monoclonal antibodies, and they offer innovative treatment options for patients with relapsed or refractory …
Resource
骨髄腫は複雑な病気ですが、骨髄腫を説明する言葉は必ずしもそうである必要はありません。以下は、骨髄腫に関する議論で一般的に使用される単語やフレーズのリストです
Resource
역학, 병태생리학, 임상적 특징, 치료 옵션 및 새롭게 떠오르는 치료법에 대한 논의를 통해 골수종에 대한 심층적인 개요를 제공합니다. 이 정보는 의료 전문가와 환자 모두에게 도움이 됩니다
Resource
Gambaran keseluruhan yang mendalam tentang myeloma, dengan perbincangan tentang epidemiologi, patofisiologi, ciri klinikal, pilihan rawatan dan rawatan baharu dan baru muncul. Maklumat ini berguna kepada profesional penjagaan kesihatan dan pesakit.
Resource
骨髄腫の詳細な概要と、疫学、病態生理学、臨床的特徴、治療の選択肢、および新しく登場した治療法について説明します。この情報は医療従事者にも患者にも同様に役立ちます
Resource
Myeloma เป็นโรคที่ซับซ้อน แต่ไม่จำเป็นต้องเป็นภาษาที่อธิบาย นี่คือรายการคำและวลีที่ใช้กันทั่วไปในการอภิปรายเกี่ยวกับ myeloma
Resource
ภาพรวมเชิงลึกของมะเร็งไขกระดูก พร้อมการอภิปรายเกี่ยวกับระบาดวิทยา พยาธิสรีรวิทยา ลักษณะทางคลินิก ทางเลือกในการรักษา และการรักษาใหม่และที่เกิดขึ้นใหม่ ข้อมูลนี้เป็นประโยชน์ต่อบุคลากรทางการแพทย์และผู้ป่วย
Resource
ด้านหนึ่งที่น่ากลัวที่สุดในการวินิจฉัยว่าเป็นมะเร็งต่อมน้ำเหลืองคือการเรียนรู้เกี่ยวกับโรคที่ไม่คุ้นเคยซึ่งค่อนข้างซับซ้อน คู่มือผู้ป่วยของ IMF สำหรับผู้ป่วยที่ได้รับการวินิจฉัยใหม่ให้ภาพรวมของมะเร็งเนื้องอก โดยมุ่งเน้นที่การวินิจฉัยที่ถูกต้องและการจำแนกประเภทการพยากรณ์โรค…
Resource
Salah satu aspek yang paling menakutkan untuk didiagnosis dengan myeloma ialah mempelajari tentang penyakit yang tidak dikenali yang agak rumit. Buku Panduan Pesakit IMF untuk Yang Baru Didiagnosa memberikan gambaran keseluruhan tentang myeloma, dengan tumpuan untuk mendapatkan diagnosis yang betul…
Resource
国際骨髄腫財団（IMF）の新たに診断された方のための患者ハンドブック は、骨髄腫をより深く理解するのに役立ちます。太字の青で書かれた言 葉の説明は、この小冊子の最後にある「用語と定義」セクションにありま す。骨髄腫関連の完全版である国際骨髄腫財団（IMF）の骨髄腫用語集は glossary.myeloma.orgにあります。
この小冊子を電子書籍版でお読みの場合は、水色のハイパーリンクから対 応するリソースにアクセスできます。国際骨髄腫財団（IMF）の出版物はすべ て無料で、…
Resource
IMF의 Patient Handbook for the Newly Diagnosed(새로운 진단을 받은 사람 을 위한 환자 핸드북) 은 다음 사항에 도움이 될 것입니다. 굵게+파란색 글꼴로 표시된 단어는 이 책자의 끝 부분에 있는 "용어 및 정의" 섹션에 설명되어 있습 니다. 골수종과 관련하여 더 완전한 편집물인 IMF의 Glossary of Myeloma Terms and Definitions (골수종 용어 및 정의 용어집) 은 glossary.myeloma.…
Resource
IMF的新诊断患者手册将帮助你更好地了解骨髓瘤。本手册末尾的“术 语和定义”章节中对粗体+蓝色字体的单词进行了解释。更完整的骨髓
瘤相关汇编，即IMF骨髓瘤术语和定义词汇表见 glossary.myeloma.org。
如果您正在阅读本手册的电子版，请点击浅蓝色的超链接访问相应资 源。IMF的所有出版物都是免费的，可以在 publications.myeloma.org下 载或索取印刷版。
Resource
The IMF InfoPack includes the following publications, free of charge.Publications helpful to all myeloma patients and care partnersIMF Patient Handbook for Multiple Myeloma: Overview of the Disease and…
Resource
This IMWG manuscript by Meletios A. Dimopoulos et al. provides an overview of the management of renal impairment in multiple myeloma patients. Renal impairment is a common complication in myeloma, occurring in around 20-25% of newly diagnosed patients and up to 50% of patients with advanced disease…
Resource
In the summer 2023 edition, IMF Chairman of the Board and Chief Scientific Officer Brian G.M. Durie, MD, discusses the 14th Annual Summit of the IMF’s International Myeloma Working Group (IMWG), as well as key data presented at the annual congresses of the American Society of Clinical Oncology…
Resource
When confronted with a diagnosis of myeloma, a cancer of the bone marrow plasma cells, many questions can arise. It is best to consult with a myeloma specialist who can give you guidance while you learn about treatment options.
Resource
In the Spring 2023 edition, Dr. Brian G.M. Durie (IMF Chairman & Chief Scientific Officer) discusses the 2023 Brian D. Novis Research Grant projects, Dr. Joseph Mikhael (IMF Chief Medical Officer) introduces the IMF’s novel initiative in myeloma for African American medical students, Robin…
Resource
The latest electronic edition of Myeloma Today is now interactive — with many helpful hyperlinks to a broad range of resources. In the Winter 2023 edition, Dr. Brian G.M. Durie (IMF Chairman & Chief Scientific Officer) discusses the key myeloma research takeaways from the 64th Annual…
Resource
The Fall edition of Myeloma Today has articles about TECVAYLI™(teclistamab-cqyv), the first-in-class bispecific BCMA-directed CD3 T-cell engager that has been granted accelerated approval by the FDA for the treatment of adult patients with relapsed or refractory myeloma, as well as a…
Resource
The Summer Myeloma Today Edition has articles on the 13th Annual Summit of the IMF’s International Myeloma Working Group (IMWG). Additionally, IMF Chief Medical Officer Dr. Joseph Mikhael provides an overview of top myeloma-related abstracts from the 2022 Annual Meetings of the American Clinical…
Resource
The Spring Myeloma Today Edition has articles on the FDA’s approval of CARVYKTI™ CAR T-cell therapy, 2022 Brian D. Novis Research Grants, Bispecific Antibodies in Myeloma and more!…
Resource
Bispecific antibody therapies are a combination of two immunotherapy approaches in one drug. Bispecifics are comprised of two monoclonal antibodies that bind to two different antigens and trigger the immune system to destroy the patient’s myeloma cells.
Resource
Primary plasma cell leukemia (PCL) is a rare and aggressive form of blood cancer that is associated with a poor prognosis. This document explores the diagnosis and prognosis of PCL in patients with multiple myeloma (MM). It highlights the importance of accurately identifying circulating plasma…